Investigating the Therapeutic Efficacy of Quality-Controlled, miR-146a-5p-Enriched Small Extracellular Vesicles Derived From MSCs Against Idiopathic Pulmonary Fibrosis.

The proposed quality control strategy ensures the stability of the product across three batches, with RNA-seq analysis revealing highly similar miRNA expression profiles. These findings help understand how sEvs impact IPF and the possible consequences of their therapeutic usage and offer a quality standard reference.

The study used Countstar Rigel S2 for flow-cytometry cell assessment in the study's cell samples during quality assessment in the 2026 Stem cell reviews and reports study.